SEARCH

SEARCH BY CITATION

References

  • 1
    Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161202.
  • 2
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 5614.
  • 3
    Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 615.
  • 4
    Begg M, Pacher P, Batkai S et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 13345.
  • 5
    Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 19469.
  • 6
    Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 2000; 61: 318.
  • 7
    Mechoulam R, Benshabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 8390.
  • 8
    Sugiura T, Kondo S, Sukagawa A et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 8997.
  • 9
    Bartho L, Benko R, Lazar Z, Illenyi L, Horvath OP. Nitric oxide is involved in the relaxant effect of capsaicin in the human sigmoid colon circular muscle. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 496500.
  • 10
    Croci T, Manara L, Aureggi G et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 1998; 125: 13935.
  • 11
    Manara L, Croci T, Guagnini F et al. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis 2002; 34: 2629.
  • 12
    Wright K, Rooney N, Feeney M et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005; 129: 43753.
  • 13
    Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002; 448: 41022.
  • 14
    Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000; 302: 7380.
  • 15
    Izzo AA, Mascolo N, Capasso R, Germano MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 2213.
  • 16
    Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249: 4449.
  • 17
    Pinto L, Izzo AA, Cascio MG et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 22734.
  • 18
    Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 212134.
  • 19
    Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ 3rd. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65: 145679.
  • 20
    Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 21
    Burton DD, Kim HJ, Camilleri M et al. Relationship of gastric emptying and volume changes after a solid meal in humans. Am J Physiol 2005; 289: G261-6.
  • 22
    Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38: 180710.
  • 23
    Chial HJ, Camilleri C, Delgado-Aros S et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil 2002; 14: 24953.
  • 24
    Castillo EJ, Delgado-Aros S, Camilleri M et al. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. Am J Physiol 2004; 287: G363-9.
  • 25
    Micromedex® Healthcare Series. Physician's Desk Reference, Vol 129, Edition 2006.
  • 26
    Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 134652.
  • 27
    Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36: 60915.
  • 28
    Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16: 178190.
  • 29
    Bouras EP, Delgado-Aros S, Camilleri M et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Gut 2002; 51: 7816.
  • 30
    Delgado-Aros S, Chial HJ, Burton DD, McKinzie S, Ferber I, Camilleri C. Reliability of the nutrient drink test to assess maximum volume intake and postprandial symptoms. Gastroenterology 2002; 122: A-550.
  • 31
    Delgado-Aros S, Kim DY, Burton DD et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol 2002; 282: G424-31.
  • 32
    McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13: 7780.
  • 33
    Bateman DN. Delta-9-tetrahydrocannabinol and gastric emptying. Br J Clin Pharmacol 1983; 15: 74951.
  • 34
    Delgado-Aros S, Camilleri M, Castillo EJ et al. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol 2005; 3: 9971006.
  • 35
    Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983; 48: 65763.
  • 36
    Lane M, Smith FE, Sullivan RA, Plasse TF. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 1990; 13: 4804.
  • 37
    Corchero J, Fuentes JA, Manzanares J. Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat. J Psychopharmacol 2002; 16: 2839.
  • 38
    Corchero J, Manzanares J, Fuentes JA. Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to delta(9)-tetrahydrocannabinol in the hypothalamus of the rat. Neuroendocrinology 2001; 74: 18592.